N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]-4-[4-[(3-pyrrolidin-1-ylphenyl)carbamoyl]phenyl]piperazine-1-carboxamide | 1092504-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]-4-[4-[(3-pyrrolidin-1-ylphenyl)carbamoyl]phenyl]piperazine-1-carboxamide
• CAS: 1092504-37-4
• 化学式: C₃₃H₃₈Cl₂N₆O₂
• 分子量: 621.61
• InChiKey: ZCUSWSZGICJYLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  43
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  71.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(1-哌嗪基)苯甲酸乙酯 在 sodium hydroxide 、 氰基磷酸二乙酯 、 水 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 249.0h， 生成 N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]-4-[4-[(3-pyrrolidin-1-ylphenyl)carbamoyl]phenyl]piperazine-1-carboxamide
  参考文献：
  名称：

  [EN] PIPERIDINE/PIPERAZINE DERIVATIVES
  [FR] DÉRIVÉS DE PIPERIDINE/PIPERAZINE

  摘要：

  公开号：

  WO2008148849A8

文献信息

• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Janssen Pharmaceutica NV

  公开号：US20150320741A1

  公开（公告）日：2015-11-12

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.

  本发明涉及DGAT抑制剂和过氧化物酶体增殖激活受体（PPAR）激动剂或其前药的组合物。本发明还涉及制备这种组合物的方法，包含该组合物的制药组合物以及该组合物作为药物的用途。本发明还涉及新型DGAT抑制剂。本发明还涉及制备这种化合物的方法，包含该化合物的制药组合物以及该化合物作为药物的用途。
• Piperidine/piperazine derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2155198B1

  公开（公告）日：2014-08-13
• Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2296659B1

  公开（公告）日：2016-12-21
• PIPERIDINE/PIPERAZINE DERIVATIVES
  申请人：Bongartz Jean-Pierre Andre Marc

  公开号：US20100210618A1

  公开（公告）日：2010-08-19

  The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —O—C(═O)—; —C(═O)—C(═O)—; —NR X —C(═O)—; —Z—C(═O)—; —Z—NR X —C(═O)—; —C(═O)—Z—; —NR X —C(═O)—Z—; —C(═S)—; —NR X —C(═S)—; —Z—C(═S)—; —Z—NR X —C(═S)—; —C(═S)—Z—; —NR X —C(═S)—Z—; Z represents a bivalent radical selected from C 1-6 alkanediyl, C 2-6 alkenediyl or C 2-6 alkynediyl; wherein each of said C 1-6 alkanediyl, C 2-6 alkenediyl or C 2-6 alkynediyl may optionally be substituted; and wherein two hydrogen atoms attached to the same carbon atom in C 1-6 alkanediyl may optionally be replaced by C 1-6 alkanediyl; Y represents —C(═O)—NR X — or —NR X —C(═O)—; R 1 represents adamantanyl, C 3-6 cycloalkyl; aryl 1 or Het 1 ; R 2 represents C 3-6 cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3-6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl or heterocycle may optionally be substituted; R 7 represents hydrogen, halo, C 1-4 alkyl, C 1-4 alkyl substituted with hydroxyl; provided that the following compounds (II), (III) are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.
• US8946228B2
  申请人：——

  公开号：US8946228B2

  公开（公告）日：2015-02-03